Antibodies that specifically bind to chemokine beta-4

Details Antibodies that specifically bind to chemokine beta-4 Antibodies that specifically bind to chemokine beta-4

2008-05-20

2008-05-20

Yaen, Christopher (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C424S130100, C424S178100

Reexamination Certificate

active

10513705

ABSTRACT:
The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to CK-B4.

REFERENCES:
patent: 4897348 (1990-01-01), Johnson et al.
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5278287 (1994-01-01), Rollins et al.
patent: 5306709 (1994-04-01), Gewirtz
patent: 5346686 (1994-09-01), Lyle et al.
patent: 5413778 (1995-05-01), Kunkel et al.
patent: 5474983 (1995-12-01), Kuna et al.
patent: 5602008 (1997-02-01), Wilde et al.
patent: 5936068 (1999-08-01), Wilde et al.
patent: 6001649 (1999-12-01), Caput et al.
patent: 6096300 (2000-08-01), Hromas
patent: 6174995 (2001-01-01), Li et al.
patent: 6673344 (2004-01-01), Li et al.
patent: 0538 030 2 (1993-04-01), None
patent: WO-90/06321 (1990-06-01), None
patent: WO-91/04274 (1991-04-01), None
patent: WO-91/12815 (1991-09-01), None
patent: WO-92/05198 (1992-04-01), None
patent: WO-92/20372 (1992-11-01), None
patent: WO-95/17092 (1995-06-01), None
patent: WO-95/31467 (1995-11-01), None
patent: WO-95/31468 (1995-11-01), None
patent: WO-96/05856 (1996-02-01), None
patent: WO-96/06169 (1996-02-01), None
patent: WO-96/09062 (1996-03-01), None
patent: WO-96/16979 (1996-06-01), None
patent: WO-96/39520 (1996-12-01), None
patent: WO-96/39521 (1996-12-01), None
patent: WO-96/39522 (1996-12-01), None
patent: WO-97/15594 (1997-05-01), None
patent: WO-97/15595 (1997-05-01), None
patent: WO-97/31098 (1997-08-01), None
patent: WO-97/35982 (1997-10-01), None
patent: WO-98/01557 (1998-01-01), None
patent: WO-98/09171 (1998-03-01), None
patent: WO-98/11226 (1998-03-01), None
patent: WO-98/14573 (1998-04-01), None
patent: WO-98/17800 (1998-04-01), None
patent: WO-98/21330 (1998-05-01), None
patent: WO-99/47674 (1999-09-01), None
patent: WO 0046248 (2000-08-01), None
PCT/GB90/02017
Rich et al., J. Managed Care Pharmacy, Aug. 2004, 10(4): 318-325.
Curse et al., Illustrated Dictionary of Immunology, 1995 by CRC press, page 241.
Amit et al., Science, 1986, vol. 233, 747-753.
Panka et al., Proc. Natl. Acad. Sci. USA, 1988, vol. 85, 3080-3084.
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982, vol. 79, 1979-1983.
Bowie, et al., Science, vol. 247: 1306-1310, 1990.
Lazar, et al. Mol. Cell. Biol., 8(3): 1247-1252, 1988.
Burgess, et al. J. Cell Biol. 111: 2129-2138, 1990.
Ngo et al., in“The Protein Folding Problem and Tediary Structure Prediction”, 1994, Merz, et al. (ed), Birkhauser, Boston, MA, pp. 433, and 492-495.
Skolnick et al., From genes to protein structure an function: novel applications of computational apporaches in the genomic era, Trends in Biotech. 18:34-39, 2000.
GenBank Accession No. AA297433 (Apr. 18, 1997).
GenBank Accession No. AA403048 (May 16, 1997).
GenBank Accession No. AA404346 (May 16, 1997).
GenBank Accession No. AA426245 (Oct. 16, 1997).
GenBank Accession No. AA739063 (Jan. 14, 1998).
GenBank Accession No. AAB38703 (Dec. 16, 1996).
GenBank Accession No. AAB61534.1 (Aug. 6, 1996).
GenBank Accession No. AAC50943.1 (Aug. 6, 1996).
GenBank Accession No. AC002482 (Aug. 21, 1997).
GenBank Accession No. AI735669 (Jun. 14, 1999).
GenBank Accession No. AI925360 (Sep. 2, 1999).
GenBank Accession No. AJ000979 (Jun. 30, 1997).
GenBank Accession No. AJ001634 (Sep. 10, 1997).
GenBank Accession No. AAW56690 (Jun. 3, 1997).
GenBank Accession No. CAA04888 (Sep. 10, 1996).
GenBank Accession No. CAA66950 (Dec. 16, 1997).
GenBank Accession No. CAB01111 (Jul. 30, 1996).
GenBank Accession No. CAB01112 (Jul. 30, 1996).
GenBank Accession No. D17181 (Jun. 21, 1993).
GenBank Accession No. D31065 (Feb. 8, 1995).
GenBank Accession No. D86955 (Mar. 6, 1997).
GenBank Accession No. I35613 (Feb. 22, 1997).
GenBank Accession No. AAR29479 (Apr. 25, 1995).
GenBank Accession No. T27336 (Dec. 6, 1994).
GenBank Accession No. T27433 (Dec. 6, 1994).
GenBank Accession No. T64134 (Feb. 17, 1995).
GenBank Accession No. T64262 (Feb. 17, 1995).
GenBank Accession No. U46767 (Dec. 14, 1996).
GenBank Accession No. U64197 (Jun. 25, 1997).
GenBank Accession No. U77035 (Jan. 23, 1997).
GenBank Accession No. W44398 (Jun. 11, 1998).
GenBank Accession No. AAW57475 (Sep. 7, 1998).
GenBank Accession No. W61279 (Sep. 24, 1998).
GenBank Accession No. X98306 (Jul. 20, 1998).
GenBank Accession No. Z77650 (Jul. 30, 1996).
GenBank Accession No. Z77651 (Jul. 30, 1996).
Geneseq Accession No. AAR95690 (Dec. 20, 1996).
Geneseq Accession No. AAW17660 (Dec. 16, 1997).
Geneseq Accession No. AAT90880 (May 21, 1998).
Geneseq Accession No. AAT90883 (May 21, 1998).
Geneseq Accession No. AAV28591 (Aug. 17, 1998).
Geneseq Accession No. AAW30191 (May 21, 1998).
Geneseq Accession No. AAW44398 (Jun. 11, 1998).
Geneseq Accession No. AAW56087 (Aug. 17, 1998).
Genseq Accession No. AAR93087 (Aug. 27, 1996).
Geneseq Accession No. AAW22670 (Mar. 19, 1998).
Geneseq Accession No. AAR29479 (Apr. 22, 1993).
Abiko, et al., “Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma,”Arch. Oral Biol.,48(2):171-175 (Feb. 2003).
Adema et al., “A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cell,”Nature,387:713-717 (Jun. 1997).
Akahoshi, et al., “Production of macrophage inflammatory protein 3 (MIP-3) (CCL20) and MIP-3 (CCL19) by human peripheral blood neurtophils in response to microbial pathogens,”Infect. Immun.,71(1):524-526 (Jan. 2003).
Ambrosini, et al., “Astrocytes are the major intracerebral source of macrophage inflammatory protein-3slaph/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro,”Glia,41(3):290-300 (Feb. 2003).
Bennouna, et al., “Cross-talk in the innate innume system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection,”J. Immunol.,171:6052-6058 (Dec. 2003).
Berger, M.S., “Isolation of Monocyte Chemotactic Protein-4,”Clinical Res.,42(2):305A (1994).
Bischoff et al., “Monocyte Chemotactic Protein 1 Is a Potent Activator of Human Basophils,”J. Exp. Med.,175:1271-1275 (May 1992).
Blum et al., “Three Human Homologs of a Murine Gene Encoding an Inhibitor of Stem Cell Proliferation,”DNA and Cell Biol.,9(8)589-602 (1990).
Brown et al., “A Family of Small Inducible Proteins Secreted by Leukocytes are Members of a New Superfamily that Includes Leukocyte and Fibroblast-Derived Inflammatory Agents, Growth Factors, and Indicators of Various Activation Processes,”J. Immunol.,142(2):679-687 (Jan. 15, 1989).
Clements et al., “Biological and Structural Properties of MIP-la Expressed in Yeast,”Cytokine,4(1):76-82 (Jan. 1992).
Craddock et al., “Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice,”Blood,90(12):4779-4788 (Dec. 15, 1997).
Crittenden, et al., “Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity,”Cancer Res.,63:5505-5512 (Sep. 1, 2003).
Der

Affiliated with

Also associated with

Rating

Antibodies that specifically bind to chemokine beta-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies that specifically bind to chemokine beta-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that specifically bind to chemokine beta-4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3947097